<DOC>
	<DOCNO>NCT01025869</DOCNO>
	<brief_summary>To investigate safety efficacy Cinatra™ Corolimus Drug Eluting Stent treatment de novo lesion native coronary artery .</brief_summary>
	<brief_title>The Clinical Evaluation Cinatra™ Corolimus-Eluting Coronary Stent De Novo Lesions Native Coronary Arteries</brief_title>
	<detailed_description>This single-arm , multicentre pilot study design provide indication effectiveness safety Cinatra™ Corolimus Eluting Coronary Stent System . The primary endpoint evaluate study late lumen loss ( in-stent ) 6 month post-procedure measure QCA 30 participant undergoing angiography timepoint . Late lumen loss define difference post-index procedure minimal lumen diameter ( MLD ) follow-up MLD .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Patient ≥ 18 year old 2 . Patient acceptable candidate percutaneous coronary intervention ( PCI ) , stenting , emergent coronary artery bypass graft ( CABG ) surgery 3 . Patient clinical evidence ischemic heart disease , stable unstable angina , silent ischemia , and/or positive functional study 4 . Female subject childbearing potential must negative pregnancy test within 7 day trial procedure 5 . Patient subject 's legal representative inform nature trial agrees provision provide write informed consent approve Hospital Research Ethics Committee ( HREC ) respective investigational site 6 . Patient agree comply specify followup evaluation return investigational site procedure perform Angiographic : 1 . Patient either single target lesion , two lesion ( target nontarget ) locate separate coronary artery 2 . If nontarget lesion treat , must treat first commercially available PTCA balloon and/or stent . Post PCI nontarget vessel , follow condition must meet : Residual diameter stenosis &lt; 10 % Absence angiographic complication Absence ischaemic symptom Absence significant new arrhythmia ECG monitoring change suggestive ischaemia 3 . Target lesion must de novo lesion native coronary artery 4 . Target lesion must ≤ 22 mm length 5 . Target lesion must stenosis ≥ 50 % &lt; 100 % 6 . Target vessel must reference vessel diameter ( RVD ) appropriate treatment 3.0mm or3.5 mm stent 7 . Target vessel must Thrombolysis Myocardial Infarction ( TIMI ) flow ≥ 2 1 . Known hypersensitivity contraindication aspirin , heparin bivalirudin , clopidogrel ticlopidine , cobalt , chromium , stent coating ( i.e . fatty acid , glyceride , alpha tocopherol ) , sensitivity contrast medium , adequately premedicated 2 . History allergic reaction significant sensitivity drug , zotarolimus , rapamycin , tacrolimus , everolimus , analogue derivative 3 . Platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ , white blood cell ( WBC ) count &lt; 3,000 cells/mm³ within 7 day prior index procedure 4 . Serum creatinine level 170 micromol/L within 7 day prior index procedure 5 . Evidence acute myocardial infarction ( MI ) within 72 hour intend trial procedure ( define : Q wave myocardial infarction ( QWMI ) nonQ wave myocardial infarction ( NQWMI ) CK enzymes &gt; 2X laboratory upper limit normal presence elevate CKMB ( amount laboratory upper limit normal ) 6 . Previous PCI target vessel within 9 month prior procedure 7 . Any planned additional PCI procedure within 30 day postindex procedure and/or plan PCI target vessel within 12 month postprocedure 8 . During index procedure , target and/or nontarget lesion ( ) require treatment device PTCA prior stent placement ( include , limited , cut balloon , atherectomy , thrombectomy , etc . ) 9 . Left ventricular ejection fraction ( LVEF ) &lt; 30 % evaluate , clinical evidence significant congestive heart failure ( NYHA Class III IV ) within prior 30 day 10 . History stroke transient ischemic attack ( TIA ) within prior 6 month 11 . Active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6 month 12 . History bleed diathesis coagulopathy refuse blood transfusion 13 . Concurrent medical condition life expectancy le 12 month 14 . Any previous treatment target vessel ( ) restenosis , include brachytherapy 16 . Any condition , Investigator 's opinion , may interfere subject 's optimal participation study 17 . Currently participate investigational drug another device trial complete primary endpoint clinically interfere current trial endpoint ; require coronary angiography , IVUS coronary artery imaging procedure Angiographic : 1 . Target lesion locate native vessel distal anastomosis saphenous vein graft left/right internal mammary artery ( LIMA/RIMA ) bypass 40 % diameter stenosis anywhere within graft 2 . Previous stenting target vessel . 3 . The target vessel lesion great 40 % diameter stenosis base visual estimate online QCA 4 . The target vessel evidence thrombus 5 . The target vessel excessively tortuous ( two bend &gt; 90º reach target lesion ) 6 . The target lesion follow characteristic : Lesion location aortoostial , unprotected leave main lesion , within 5 mm origin leave anterior descending ( LAD ) leave circumflex ( LCX ) Involves side branch &gt; 2.0 mm diameter Is distal &gt; 45º bend vessel Is severely calcified 7 . Unprotected leave main coronary artery disease ( obstruction great 50 % leave main coronary artery )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>